Compounds, compositions, methods of synthesis, and methods of treatment

Abstract

The present disclosure relates to organic chemistry and in particular to a series of corticotropin releasing factor type-1 (CRF 1 ) receptor ligand compounds and compositions, as well as methods of preparation and treatment.

1 - 24 . (canceled) 
     
     
         25 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
         and a pharmaceutically acceptable salt of any of the foregoing comprising a label selected from the group consisting of:  2 H,  3 H,  11 C,  13 N,  14 C,  32 Cl,  13 N,  18 F,  75 Br,  76 Br,  123 I,  124 I,  125 I, and  131 I wherein:
 R 1  is selected from the group consisting of 
 
       
       
         
           
           
               
               
           
         
         
           R 2  is selected from the group consisting of: H, alkyl, and haloalkyl; 
           R 4  is independently selected from the group consisting of: —H, —X, alkyl, haloalkyl, —OH, —O-alkyl, —O-haloalkyl, and —Sn(alkyl) 3 , wherein o is 1, 2, or 3; 
           each R 9  are independently selected from the group consisting of: H, halogen, alkyl, haloalkyl, and heteroalkyl; 
           R 10  is selected from the group consisting of: H, halogen, alkyl, haloalkyl, and heteroalkyl; 
           R 11  is selected from the group consisting of: 
         
       
       
         
           
           
               
               
           
         
         
           R 12  is selected from the group consisting of: H, —OH, —O-alkyl, alkyl, X, haloalkyl, and heteroalkyl; 
           R 13  is selected from the group consisting of: H, alkyl, haloalkyl, and heteroalkyl; 
           R 14  is selected from the group consisting of: H, halogen, alkyl, haloalkyl, and heteroalkyl; 
           R 15  is selected from the group consisting of: H, halogen, alkyl, haloalkyl, and heteroalkyl; 
         
         X is a halogen;
 X 2  is selected from the group consisting of: H, alkyl, —X, and —Sn(alkyl) 3 ; 
 y is selected from the group consisting of: 1 or 2; and 
 z is selected from the group consisting of: 1, 2, or 3. 
 
       
     
     
         26 . The compound of formula (3), according to  claim 25 , wherein R 9  is H and R 10  is methyl, and a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         27 . The compound of formula (4), according to  claim 25 , wherein R 9  is H and R 10  is methyl, and a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         28 . The compound of formula (5), according to  claim 25 , wherein R 9  is H and R 10  is methyl, and a stereoisomer thereof, and a pharmaceutically acceptable salt of any of the foregoing. 
     
     
         29 . A pharmaceutical composition comprising a compound of any one of  claim 25  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.